CRISPR Therapeutics AG (CRSP) Cash from Financing Activities (2015 - 2026)

CRISPR Therapeutics AG has disclosed Cash from Financing Activities across 12 years of filings, most recently posting $7.2 million for Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 217.98% year-over-year to $7.2 million; the TTM figure through Jun 2026 stood at $1.0 billion (up 2471.69% YoY), while the FY2025 annual figure was $426.0 million, up 28.33% from the prior year.
• Cash from Financing Activities came in at $7.2 million for Q2 2026 at CRISPR Therapeutics AG, down from $591.9 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $591.9 million in Q1 2026 to a low of -$466000.0 in Q2 2024.
• Average Cash from Financing Activities over 5 years is $81.0 million, with a median of $10.6 million recorded in 2022.
• The largest YoY upside for Cash from Financing Activities was 5561.25% in 2024 against a maximum downside of 102.78% in 2024.
• Over 5 years, Cash from Financing Activities stood at $2.5 million in 2022, then surged by 1471.39% to $38.9 million in 2023, then slumped by 56.66% to $16.9 million in 2024, then jumped by 589.82% to $116.4 million in 2025, then plunged by 93.83% to $7.2 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $7.2 million in Q2 2026, $591.9 million in Q1 2026, and $116.4 million in Q4 2025.